When released, S100A8/A9 can signal through the receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4) to promote tumor-associated inflammation and progression of advanced stage adenocarcinomas and colitis-associated cancer [8]–[11]. The gene discussed is TLR4; the disease is neoplasm.